The boom in weight-loss drugs may have transformed the obesity market, but Novo Nordisk’s CEO says the industry is still only scratching the surface with tens of millions of Americans potentially eligible for treatment.
Novo Nordisk President and CEO Mike Doustdar joined FOX Business’ Cheryl Casone on “Mornings with Maria” to discuss the adoption of GLP-1 drugs, their potential economic impact and the company’s outlook for medicines, including Wegovy.
“We are clearly at early innings,” Doustdar said, pointing to the large population living with obesity and relatively limited use of GLP-1 medications. He said more than 100 million people in the U.S. are suffering from obesity, while “somewhere around ten...
Read the full article here
